A recent study has demonstrated a highly dynamic pharmacokinetic of infliximab in patients with autoimmune disorders; patients with Crohn’s disease exhibited a higher terminal elimination half-life of the infliximab-TNF complex in comparison to patients with RA and ankylosing spondylitis [164]. This evidence concerns the gene TNF and rheumatoid arthritis.